Significant predictors for olanzapine pharmacokinetics: a systematic review of population pharmacokinetic studies

References

• Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389–409. DOI:10.2165/00023210-200620050-00004
   PubMed Web of Science ®Google Scholar
• Ennis C, Kemp JD, Cox B. Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J Neurochem. 1981;36(4):1515–1520.
   PubMed Web of Science ®Google Scholar
• Matsui-Sakata A, Ohtani H, Sawada Y. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet. 2005;20(3):187–199.
   PubMedGoogle Scholar
• Lund BC, Perry PJ. Olanzapine: an atypical antipsychotic for schizophrenia. Expert Opin Pharmacother. 2000;1(2):305–323.
   PubMedGoogle Scholar
• Mauri MC, Paletta S, Di Pace C, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet. 2018;57(12):1493–1528. DOI:10.1007/s40262-018-0664-3
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177–193. DOI:10.2165/00003088-199937030-00001
   PubMed Web of Science ®Google Scholar
• Söderberg MM, Dahl ML. Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 2013;14(11):1319–1336.
   PubMed Web of Science ®Google Scholar
• Sheehan JJ, Sliwa JK, Amatniek JC, et al. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010;11(6):516–525. DOI:10.2174/138920010791636202
   PubMed Web of Science ®Google Scholar
• Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48(2):157–165. DOI:10.1177/0091270007310385
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr., Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacol (Berl). 1996;124(1–2):159–167. DOI:10.1007/BF02245617
   PubMed Web of Science ®Google Scholar
• Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214–232. DOI:10.1002/wps.20765
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):411–459.
   PubMedGoogle Scholar
• Sasaki T, Tabuchi H, Higuchi S, et al. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics. 2009;10(8):1257–1266. DOI:10.2217/pgs.09.65
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Kanji S, Hayes M, Ling A, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783–795. DOI:10.1007/s40262-015-0236-8
   PubMed Web of Science ®Google Scholar
• Jamsen KM, McLeay SC, Barras MA, et al. Reporting a population pharmacokinetic-pharmacodynamic study: a journal’s perspective. Clin Pharmacokinet. 2014;53(2):111–122. DOI:10.1007/s40262-013-0114-1
   PubMed Web of Science ®Google Scholar
• Duffull SB, Wright DF. What do we learn from repeated population analyses? Br J Clin Pharmacol. 2015;79(1):40–47.
   PubMed Web of Science ®Google Scholar
• Christians U, Klawitter J, Clavijo CF. Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney Int Suppl. 2010;2010(115):S1–7.
   Google Scholar
• Catafau AM, Penengo MM, Nucci G, et al. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol. 2008;22(8):882–894. DOI:10.1177/0269881107083810
   PubMed Web of Science ®Google Scholar
• Lobo ED, Robertson-Plouch C, Quinlan T, et al. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model. Paediatr Drugs. 2010;12(3):201–211. DOI:10.2165/11532580-000000000-00000
   PubMedGoogle Scholar
• Pilla Reddy V, Kozielska M, Suleiman AA, et al. Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility. Schizophr Res. 2013;146(1–3):144–152. DOI:10.1016/j.schres.2013.02.011
   PubMed Web of Science ®Google Scholar
• Pilla Reddy V, Kozielska M, Suleiman AA, et al. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score. Schizophr Res. 2013;146(1–3):153–161. DOI::10.1016/j.schres.2013.02.010
   PubMed Web of Science ®Google Scholar
• Davies SJ, Mulsant BH, Flint AJ, et al. The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD. Clin Pharmacokinet. 2015;54(11):1161–1168. DOI:10.1007/s40262-015-0275-1
   PubMed Web of Science ®Google Scholar
• Tylutki Z, Jawień W, Ciszowski K, et al. Abnormal olanzapine toxicokinetic profiles–population pharmacokinetic analysis. Toxicol Mech Methods. 2015;25(1):1–12. DOI::10.3109/15376516.2014.971137
   PubMed Web of Science ®Google Scholar
• Yin A, Shang D, Wen Y, et al. Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis. Eur J Clin Pharmacol. 2016;72(8):933–944. DOI:10.1007/s00228-016-2040-2
   PubMed Web of Science ®Google Scholar
• Li A, Ji S, Yue W, et al. Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia. BMJ Open. 2018;8(8):e020070. DOI:10.1136/bmjopen-2017-020070
   PubMed Web of Science ®Google Scholar
• Maharaj AR, Wu H, Zimmerman KO, et al. Population pharmacokinetics of olanzapine in children. Br J Clin Pharmacol. 2021;87(2):542–554. DOI:10.1111/bcp.14414
   PubMed Web of Science ®Google Scholar
• Sun L, Mills R, Sadler BM, et al. Population pharmacokinetics of olanzapine and samidorphan when administered in combination in healthy subjects and patients with schizophrenia. J Clin Pharmacol. 2021;61(11):1430–1441. DOI:10.1002/jcph.1911
   PubMed Web of Science ®Google Scholar
• Wang X, Hang Y, Zhou H, et al. Prediction of steady-state plasma concentrations of olanzapine in Chinese Han in patients based on a retrospective population pharmacokinetic model [Article]. Trop J Pharm Res. 2021;20(11):2433–2441. DOI:10.4314/tjpr.v20i11.28
   Web of Science ®Google Scholar
• Xiao T, Wang Z, Li G, et al. What to do about missed doses? a retrospective study of olanzapine in the elderly. Drug Des Devel Ther. 2021;15:3411–3423.
   PubMed Web of Science ®Google Scholar
• Zang YN, Dong F, Li AN, et al. The impact of smoking, sex, infection, and comedication administration on oral olanzapine: a population pharmacokinetic model in Chinese psychiatric patients. Eur J Drug Metab Pharmacokinet. 2021;46(3):353–371. DOI:10.1007/s13318-021-00673-5
   PubMed Web of Science ®Google Scholar
• Bever KA, Perry PJ. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. Am J Health Syst Pharm. 1998;55(10):1003–1016.
   PubMed Web of Science ®Google Scholar
• Leeder JS, Kearns GL. Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am. 1997;44(1):55–77.
   PubMed Web of Science ®Google Scholar
• Kennedy M. Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. Clin Pharmacol Ther. 2008;84(6):662–673.
   PubMed Web of Science ®Google Scholar
• McLachlan AJ, Pont LG. Drug metabolism in older people–a key consideration in achieving optimal outcomes with medicines. J Gerontol A Biol Sci Med Sci. 2012;67(2):175–180.
   PubMed Web of Science ®Google Scholar
• Pollock BG, Wylie M, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol. 1999;39(9):936–940. DOI:10.1177/00912709922008560
   PubMed Web of Science ®Google Scholar
• Karastergiou K, Smith SR, Greenberg AS, et al. Sex differences in human adipose tissues - the biology of pear shape. Biol Sex Differ. 2012;3(1):13. DOI:10.1186/2042-6410-3-13
   PubMedGoogle Scholar
• Ereshefsky L, Jann MW, Saklad SR, et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry. 1985;20(3):329–332. DOI:10.1016/0006-3223(85)90063-0
   PubMed Web of Science ®Google Scholar
• Perera V, Gross AS, McLachlan AJ. Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry. Clin Pharmacol Ther. 2012;92(4):511–519.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62. DOI:10.1055/s-0043-116492
   PubMed Web of Science ®Google Scholar
• Perera V, Gross AS, Polasek TM, et al. Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opin Drug Metab Toxicol. 2013;9(9):1115–1137. DOI:10.1517/17425255.2013.795540
   PubMed Web of Science ®Google Scholar
• Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76(2):178–184.
   PubMed Web of Science ®Google Scholar
• Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol. 2005;97(3):125–134.
   PubMed Web of Science ®Google Scholar
• Chiu CC, Lane HY, Huang MC, et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol. 2004;44(12):1385–1390. DOI:10.1177/0091270004270291
   PubMed Web of Science ®Google Scholar
• Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993;45(6):1211–1214. DOI:10.1016/0006-2952(93)90272-X
   PubMed Web of Science ®Google Scholar
• Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 2001;23(4):410–413. DOI:10.1097/00007691-200108000-00015
   PubMed Web of Science ®Google Scholar
• DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41(15):1247–1266.
   PubMed Web of Science ®Google Scholar
• Urichuk L, Prior TI, Dursun S, et al. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9(5):410–418. DOI:10.2174/138920008784746373
   PubMed Web of Science ®Google Scholar
• Schwenger E, Dumontet J, Ensom MH. Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia? Clin Pharmacokinet. 2011;50(7):415–428.
   PubMed Web of Science ®Google Scholar
• Zhang K, Tartarone A, Pérez-Ríos M, et al. Smoking burden, MPOWER, future tobacco control and real-world challenges in China: reflections on the WHO report on the global tobacco epidemic 2021. Transl Lung Cancer Res. 2022;11(1):117–121. DOI:10.21037/tlcr-22-27
   PubMed Web of Science ®Google Scholar
• Gorman BK, Lariscy JT, Kaushik C. Gender, acculturation, and smoking behavior among U.S. Asian and Latino immigrants. Soc Sci Med. 2014;106:110–118.
   PubMed Web of Science ®Google Scholar
• Smith PH, Bessette AJ, Weinberger AH, et al. Sex/Gender differences in smoking cessation: a review. Prev Med. 2016;92:135–140.
   PubMed Web of Science ®Google Scholar
• Brunette MF, O’Keefe C, Zimmet S, et al. Clozapine, olanzapine, or typical antipsychotics for alcohol use disorder in patients with schizophrenia. J Dual Diagn. 2008;4(4):344–354. DOI:10.1080/15504260802313816
   Web of Science ®Google Scholar
• Littlewood RA, Claus ED, Arenella P, et al. Dose specific effects of olanzapine in the treatment of alcohol dependence. Psychopharmacology. 2015;232(7):1261–1268. DOI:10.1007/s00213-014-3757-1
   PubMed Web of Science ®Google Scholar
• Littrell KH, Petty RG, Wolf NM. Olanzapine: a 5-year perspective. Expert Rev Neurother. 2006;6(6):811–821.
   PubMedGoogle Scholar
• McLoughlin BC, Pushpa-Rajah JA, Gillies D, et al. Cannabis and schizophrenia. Cochrane Database Syst Rev. 2014;2014(10):Cd004837. DOI:10.1002/14651858.CD004837.pub3
   PubMedGoogle Scholar
• Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005;193(6):379–386. DOI:10.1097/01.nmd.0000165089.14736.bf
   PubMed Web of Science ®Google Scholar
• Nasrin S, Coates S, Bardhi K, et al. Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD). Chem Res Toxicol. 2023;36(2):177–187. DOI:10.1021/acs.chemrestox.2c00259
   PubMedGoogle Scholar
• Zhan M, Hou S, Zhan CG, et al. Kinetic characterization of high-activity mutants of human butyrylcholinesterase for the cocaine metabolite norcocaine. Biochem J. 2014;457(1):197–206. DOI:10.1042/BJ20131100
   PubMedGoogle Scholar